# US 2018/0021297 A1 · Use Of Croton- Or Calophyllum-Derived Proanthocyanidin Polymers Or Botanical Extracts In Combination With Rifaximin For The Treatment Of Diarrhea In Non-Human Animals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021297 A1
- Document ID: US20180021297A1
- Status: Published application
- Kind: A1
- Application number: 15/551,670
- Filed: 2016-02-24
- Published: 2018-01-25
- Earliest claimed: 2015-02-26
- Assignees: Jaguar Health, Inc.
- Applicants: Jaguar Health, Inc.
- Inventors: Michael Hauser
- Web page: https://patentgrep.com/patent/US20180021297A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A23K 20/121: containing oxygen or sulfur as hetero atom
- A23K 20/195: Antibiotics
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 36/47: Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER

## Abstract

Provided are combination therapy methods and uses for treating diarrhea, particularly malabsorption diarrhea, in neonatal, young and adult non-human animals, particularly for treating diarrhea resulting from microbial infection of the animals, with a therapeutically effective amount of a proanthocyanidin polymer from Croton lechleri, in either enteric or non-enteric form, in combination with a therapeutically effective amount of the antimicrobial agent rifaximin.

## Claims

### Claim 1

A method of treating diarrhea in a non-human animal, the method comprising orally administering to the non-human animal in need thereof a combination therapy comprising an aqueous soluble proanthocyanidin polymer from Croton lechleri and the antimicrobial agent rifaximin in amounts effective to treat the diarrhea in the non-human animal.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the C. lechleri proanthocyanidin polymer is administered as an enteric coated pharmaceutical composition.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the C. lechleri proanthocyanidin polymer is administered as a non-enteric pharmaceutical composition.

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the non-human animal is a juvenile animal.

### Claim 5 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the non-human animal is an adult animal.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any of claims 1 to 5, wherein the non-human animal is selected from cattle, horses, camels, bison, buffalo, sheep, pigs, goats, rabbits, dogs and cats.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1 to 6, wherein the C. lechleri proanthocyanidin polymer is administered in an amount of 250 mg twice daily in combination with rifaximin.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method according to any one of claims 1 to 7, wherein rifaximin is administered in a solid dosage form in combination with the C. lechleri proanthocyanidin polymer.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 1 to 8, wherein rifaximin is administered in a dose of 20 mg to 1000 mg.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method according to any one of claims 1 to 9, wherein rifaximin is administered in a dose of 200 mg or 550 mg.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method according to any one of claims 1 to 10, wherein the C. lechleri proanthocyanidin polymer is administered as powder reconstituted with a liquid selected from oral electrolytes, milk, milk replacer, physiological saline, or water in combination with rifaximin.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method according to any one of claims 1 to 11, wherein the C. lechleri proanthocyanidin polymer is administered as a bolus in combination with rifaximin.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1 to 12, wherein the C. lechleri proanthocyanidin polymer is administered in animal feed or drink.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method according to any one of claims 1 to 13, wherein the C. lechleri proanthocyanidin polymer is formulated in the form of a gel, paste, or gel paste.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the gel, paste, or gel paste is administered to the animal by topical application to the roof of the animal's mouth.

### Claim 16 (depends on 14, 15)

The method according to claim 14 or claim 15 wherein the gel, paste, or gel paste is contained in a delivery device.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the delivery device is a syringe.

### Claim 18 (depends on 14, 15, 16, 17)

The method according to any one of claims 14 to 17, wherein the gel, paste, or gel paste comprises polymeric microparticles or nanoparticles containing the C. lechleri proanthocyanidin polymer in combination with rifaximin.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the polymeric microparticles or nanoparticles are pH-sensitive.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein the C. lechleri proanthocyanidin polymer is administered to the animal in an amount of at least 50 mg to 250 mg and rifaximin is administered to the animal in an amount of at least 50 mg to 600 mg.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method according to any one of claims 1 to 20, wherein symptoms associated with the diarrhea in the non-human animal include dehydration and electrolyte loss.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method according to any one of claims 1 to 21, wherein the C. lechleri proanthocyanidin polymer composition is selected from the group consisting of SB 300, SP 303 and crofelemer.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the C. lechleri proanthocyanidin polymer composition is SB 300.

### Claim 24 (depends on 18)

The method according to claim 18, wherein the paste comprises enteric coated SB 300 and is administered to the animal in an amount of 2 mg/kg twice a day for three days.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the paste is administered twice a day, twelve hours apart.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method according to any one of claims 1 to 25, wherein the rifaximin is administered to the animal at the same time as the aqueous soluble proanthocyanidin polymer from Croton lechleri is administered.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method according to any one of claims 1 to 25, wherein the rifaximin is administered to the animal before the aqueous soluble proanthocyanidin polymer from Croton lechleri is administered.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method according to any one of claims 1 to 25, wherein the rifaximin is administered to the animal after the aqueous soluble proanthocyanidin polymer from Croton lechleri is administered.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method according to any one of claims 1 to 25, wherein a composition comprising effective amounts of the aqueous soluble proanthocyanidin polymer from Croton lechleri and rifaximin and a pharmaceutically acceptable carrier, vehicle, or excipient is administered to the animal.

### Claim 30

A kit comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an aqueous soluble proanthocyanidin polymer from Croton lechleri; the second container comprises at least one dose of a medicament comprising rifaximin; and the package insert comprises instructions for use in treating a non-human animal for diarrhea.

### Claim 31

A method for treating bacteria-induced diarrhea in a young or adult non-human animal, said method comprising administering to the animal a combination therapy which comprises an aqueous soluble proanthocyanidin polymer from Croton lechleri and rifaximin in amounts effective to treat the diarrhea.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claims 1 to 31, wherein the combination of rifaximin and a C. lechleri proanthocyanidin polymer, composition, or botanical extract thereof provides localized and targeted activity against diarrhea-causing pathogens in the enteric environment of the GI tract of the animal undergoing treatment and is not systemically absorbed.

### Claim 33 (depends on 32)

The method according to claim 32, wherein consumable products derived or produced from a non-human animal treated with the combination of rifaximin and a C. lechleri proanthocyanidin polymer, composition, or botanical extract thereof contain insignificant residual amounts of the rifaximin and/or the C. lechleri proanthocyanidin polymer, composition, or botanical extract components, or breakdown products thereof, of the combination therapy.

### Claim 34 (depends on 32)

The method according to claim 32, wherein resistance to the rifaximin and/or the C. lechleri proanthocyanidin polymer, composition, or botanical extract components, or breakdown products thereof, of the combination therapy is minimized or absent in the treated non-human animals and in consumable products derived therefrom.

### Claim 35

A method of treating diarrhea in a non-human animal, the method comprising orally administering to the non-human animal in need thereof a composition comprising rifaximin in amounts effective to treat the diarrhea in the non-human animal.

### Claim 36 (depends on 35)

The method according to any one of claim 35, wherein the non-human animal is a juvenile animal.

### Claim 37 (depends on 35)

The method according to any one of claim 35, wherein the non-human animal is an adult animal.

### Claim 38 (depends on 35, 36, 37)

The method according to any of claims 35 to 37, wherein the non-human animal is selected from cattle, horses, camels, bison, buffalo, sheep, pigs, goats, rabbits, dogs and cats.

### Claim 39 (depends on 35, 36, 37, 38)

The method according to any one of claims 35 to 38, wherein rifaximin is administered in a dose of 20 mg to 1000 mg.

### Claim 40 (depends on 35, 36, 37, 38, 39)

The method according to any one of claims 35 to 39, wherein rifaximin is administered in a dose of 200 mg or 550 mg.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The method according to any one of claims 35 to 40, wherein rifaximin is administered in animal feed or drink.

### Claim 42 (depends on 35, 36, 37, 38, 39, 40, 41)

The method according to any one of claims 35 to 41, wherein symptoms associated with the diarrhea in the non-human animal include dehydration and electrolyte loss.

### Claim 43

A method for treating bacteria-induced diarrhea in a young or adult non-human animal, said method comprising administering to the animal rifaximin in an amount effective to treat the diarrhea.

### Claim 44 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method according to any one of claims 35 to 43, wherein rifaximin provides localized and targeted activity against diarrhea-causing pathogens in the enteric environment of the GI tract of the animal undergoing treatment and is not systemically absorbed.

### Claim 45 (depends on 44)

The method according to claim 44, wherein consumable products derived or produced from a non-human animal treated with rifaximin contain insignificant residual amounts of the rifaximin or breakdown products thereof.

### Claim 46 (depends on 44)

The method according to claim 44, wherein resistance to the rifaximin is minimized or absent in the treated non-human animals and in consumable products derived therefrom.
